Approved for use through 11/30/2007 CMB 0851-0031

U.S. Patent and Trademark Office; U.S. DePARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

NFORMATION DISCLOSURE STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	Application Number		10577814		
	Filing Date		2006-04-28		
	First Named Inventor Judy Lieberman				
	Art Unit		1635		
Not for Submission under or of it 1.55,	Examiner Name				
	Attorney Docket Numb	er	033393-055222		

U.S.PATENTS						Remove					
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue D	)ate	Name of Pate of cited Docu	entee or Applicant ment	Releva	es,Columns,Lines where vant Passages or Relevant res Appear		
	1	6228642	B1	2001-05	i-08	Baker et al.					
If you wish to add additional U.S. Patent citation information please click the Add button.								Add			
U.S.PATENT APPLICATION PUBLICATIONS Remove											
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	Name of Pate of cited Docu	entee or Applicant ment	Releva	ges,Columns,Lines where evant Passages or Relevant ures Appear		
	1										
If you wish to add additional U.S. Published Application citation information please click the Add button. Add											
				FOREIC	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Kind Code <sup>2</sup> j Code <sup>4</sup>		Publication Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		T5	
	1										
If you wish to add additional Foreign Patent Document citation information please click the Add button Add											
NON-PATENT LITERATURE DOCUMENTS Remove											
Examiner Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (look, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								T5			

Receipt date: 12/18/2007 10577814 - GAU: 1635 Application Number 10577814 Filing Date 2006-04-28 INFORMATION DISCLOSURE First Named Inventor Judy Lieberman STATEMENT BY APPLICANT Art Unit 1635 ( Not for submission under 37 CFR 1.99) **Examiner Name** Attorney Docket Number 033393-055222

	1	ASHKENAZI, A. and DIXIT, V.M. Science 281:1305-1308 (1998)	
	2	CHIU & RANA, RNA 9:1034-1048 (2003)	
	3	DEL ZOPPO, G.J., K.M.A. Welch, L.R. Caplan, D.J. Reis, et al., (Eds.) pp.217-220 Academic Press, San Diego (1997)	
	4	FLOYD & CARNEY, Ann. Neurol. 32:S22-S27 (1992)	
	5	GREEN, D.R. and EVAN, G.I. Cancer Cell 1:19-30 (2002)	
	6	HAMADA et al., Antisense Nucleic Acid Drug Dev. 12:301-309 (2002)	
	7	HERWEIJER & WOLFF, Gene Therapy 10:453-458 (2003)	
	8	HEYMAN et al., Curr. Opin.Crit. Care. 8(6):526-34 (2002)	
	9	JACKSON et al., Nat. Biotechnol. 21(6):635-637 (2003)	
	10	LIU, K.D., Crit. Care Med. 31(8)(Suppl.):S572-S581 (2003)	
Ī	11	LEE et al., Am. J. Physiol. Heart Cicr. Physiol. 284:H456-H463 (2003)	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

Receipt date: 12/18/2007 10577814 - GAU: 1635 Application Number 10577814 Filing Date 2006-04-28 INFORMATION DISCLOSURE First Named Inventor Judy Lieberman STATEMENT BY APPLICANT Art Unit 1635 ( Not for submission under 37 CFR 1.99) **Examiner Name** Attorney Docket Number 033393-055222

12	LEWIS et al., Nature Genetics 32:107-108 (2002)	
13	MARUYAMA et al., J. Gene. Med. 4:333-341 (2002)	
14	MARUYAMA et al., Hum. Gene Ther. 13.455-468 (2002)	
15	MATTSON, M.P. Nat. Rev. Mol. Cell. Biol. 1:120-128 (2002)	
16	MCCAFFREY et al., Nature 418:38-39 (2002)	
17	MENÈ et al., J. Nephrol. 16:186-195 (2003)	
18	MEIER, P., et al., Nature 407:796-801 (2000)	
19	MOGI et al., Lab. Invest. 81(2):177-184 (2001)	
20	NAGATA & SUDA, Immunology Today 16(1):39-43 (1995)	
21	NANSEN et al., Blood 99(4):1237-1245 (2002)	
22	NOGAE et al., J. Am. Soc. Nephrol. 9(4):620-631 (1998)	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

Receipt date: 12/18/2007 10577814 - GAU: 1635 Application Number 10577814 Filing Date 2006-04-28 INFORMATION DISCLOSURE First Named Inventor Judy Lieberman STATEMENT BY APPLICANT Art Unit 1635 ( Not for submission under 37 CFR 1.99) **Examiner Name** Attorney Docket Number 033393-055222

23	ORTIZ et al., Current Drug Targets – Immune, Endocrine & Metabolic Disorders 2:181-192 (2002)	
24	PASCHEN, W., J. Cereb. Blood Flow Metab. 23(7):773-779 (2003)	
25	PRAKASH et al., Ren. Fall. 25(2):225-233 (2003)	
26	RATHMELL, J.C. and THOMPSON, C.B. Cell 109 (Suppl.): S97-S107 (2002)	
27	REITER et al., Ann. N.Y. Acad. Sci. 993:35-47 (2003)	
28	ROWE, P.M., Glimmers of clinical relevance for Fas (1996) Lancet, 347: 1398	
29	SATA & WALSH, J. Biol. Chem. 273(50):33103-33106 (1998)	
30	SCAFFIDI et al., J. Biol. Chem. 274(3):1541-1548 (1999)	
31	SLEDZ et al., Nat. Cell Biol. 5(9):834-839 (2003)	
32	SONG et al., Nat. Med. 9(3):347-351 (2003)	
33	SØRENSEN, Dag R. et al., J. Mol. Biol., 327:761-766 (2003)	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

First Named Inventor   Judy Lieberman	_
Not for submission under 37 CFR 1.99)  Art Unit 1635  Examiner Name	_
Examiner Name	_
Attorney Docket Number 033393-055222	_
34 TEOH & FARRELL, J. Gastroenterol. Hepatol. 18:891-902 (2003)	
35 THADHANI et al., N. Engl. J. Med. 334:1448-60 (1996)	
36 VAUX, D.L. and KORSMEYER, S.J. Cell 96:245-254 (1999)	
37 VERMUELEN, K., et al. Cell Prolif. 36:165-175 (2003)	
38 WALL, Nathan R. et al., The Lancet; 362:1401-1403 (2003)	
39 WATANABE-FUKUNAGA, R., et al., J. Immunol., 148:1274-1279 (1992)	
40 ZHANG et al., Hum. Gene Ther. 10:1735-1737 (1999)	
41 ZHANG et al., J. Biol. Chem. 277(40):37430-37438 (2002)	
42 ZÖRNIG, M., et al., Biochim. Biophys. Acta 1551.F1-F37 (2001)	
f you wish to add additional non-patent literature document citation information please click the Add button Add	_
EXAMINER SIGNATURE	
Examiner Signature /Sean Mcgarry/ Date Considered 09/28/2009	

Application Number

10577814

10577814 - GAU: 1635

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

Receipt date: 12/18/2007